Bladder cancer clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 10, 2006, Pages 984-1014

  Montie, James E ^a   Abrahams, Neil A ^a   Bahnsonmario, Robert R ^a   Eisenberger, Mario A ^a   El Galley, Rizk ^a   Herr, Harry W ^a   Hudes, Gary R ^a   Kuzel, Timothy M ^a   Lange, Paul H ^a   Patterson, Anthony ^a   Pollack, Alan ^a   Richie, Jerome P ^a   Sexton, Wade J ^a   Shipley, William U ^a   Small, Eric J ^a   Trump, Donald L ^a   Walther, Phillip J ^a   Wilson, Timothy G ^a  

^a NONE

Author keywords

Bladder cancer; Chemotherapy; NCCN clinical practice guidelines; Radiation therapy; Radical cystectomy; Urology; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINBLASTINE;

BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CYSTECTOMY; DOSE RESPONSE; HISTOLOGY; HUMAN; METASTASIS; NEPHROURETERECTOMY; ONSET AGE; PATHOLOGY; PATIENT CARE; PROGNOSIS; PROSTATE CARCINOMA; TRANSITIONAL CELL CARCINOMA; URETER TUMOR;

EID: 33751582571     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0083     Document Type: Conference Paper

References (39)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society, 2006.
2. Brodsky GL. Pathology of bladder carcinoma. Hematol Oncol Clin North Am 1992;6:59-80.
3. Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus: report of 7 cases and review of literature. Urology 1983;21:360-366.
4. Herr HW. Urachal carcinoma: the case for extended partial cystectomy. J Urol 1994;151:365-366.
5. Reuter V. Pathology of bladder cancer: assessments of prognostic variables in response therapy. Semin Oncol 1990;17:524-532.
6. Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
7. Hall RR, Parmar MK, Richards AB, Smith PH. Changes in cysroscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308:257-260.
8. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: AJCC Springer-Verlag, 2002.
9. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
10. Murphy WM. Classification of urothelial neoplasms; one, two, three, around we go. Urol Oncol 2001;6:69-71.
11. Busch C, Hawes D, Johansson S, Cote R. Pathologic assessment of bladder cancer and pitfalls in staging. In: Droller MJ, ed. Bladder Cancer, Current Diagnosis and Treatment. Totowa, NJ: Humana Press, 2001:149-182.
12. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105-108.
13. Check W. Bladder biopsies in step with clinical side. CAP Today (College of American Pathologists) 2004;18:43-54.
14. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer Press, 2004.
15. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. 4th series. Washington (DC): American Registry of Pathology, 2004.
16. Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol 1999;162:1697-1701.
17. Herr H, Sogni PC. Does early cystectomy improve survival of patients with high-risk superficial bladder tumors? J Urol 2001;166:1296-1299.
18. Tanimoto A, Yuasa Y, Imai Y, et al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 1992;185:741-747.
19. Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology 1994;193:239-245.
20. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
21. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297-303.
22. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561-569.
23. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738-747.
24. Scher HI. Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin Oncol 1990;17:555-565.
25. Kata EJ, Herr H. The role of transurethral resection for muscle invasive bladder carcinoma [abstract]. J Urol 1993;149:316A. Abstract.
26. Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am 1993;19:701-711.
27. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol 1998;16:3576-3583.
28. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-67.
29. Rotman M, Aziz H. Concomitant continuous infusion chemotherapy and radiation. Cancer 1990;65:823-835.
30. Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693-699.
31. Russell KJ, Boileau MA, Ireton RC, et al. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 1988;167:845-848.
32. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-2157.
33. Orsatti M, Curotto A, Canobbio L, et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33:173-178.
34. Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:1673-1677.
35. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 2001;19:2638-2646.
36. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-500.
37. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. J Clin Oncol 1985;3:1463-1470.
38. Lorusso V, Manzione L, de Vita F, et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:53-56.
39. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.